US Edition
Q2 EPS Estimate for Gain Therapeutics Reduced by Analyst
Summary by americanbankingnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Q2 EPS Estimate for Gain Therapeutics Reduced by Analyst
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Research analysts at Roth Capital cut their Q2 2025 earnings per share (EPS) estimates for Gain Therapeutics in a research note issued on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.18) per share for the quarter, down […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
